Randomized outcome trial of nutrient-enriched formula and neurodevelopment outcome in preterm infants by Maria Lorella Giannì et al.
Giannì et al. BMC Pediatrics 2014, 14:74
http://www.biomedcentral.com/1471-2431/14/74RESEARCH ARTICLE Open AccessRandomized outcome trial of nutrient-enriched
formula and neurodevelopment outcome in
preterm infants
Maria Lorella Giannì*, Paola Roggero, Orsola Amato, Odoardo Picciolini, Pasqua Piemontese, Nadia Liotto,
Francesca Taroni and Fabio MoscaAbstract
Background: Preterm infants are at risk for adverse neurodevelopment. Furthermore, nutrition may play a key role
in supporting neurodevelopment. The aim of this study was to evaluate whether a nutrient-enriched formula fed to
preterm infants after hospital discharge could improve their neurodevelopment at 24 months (term-corrected age).
Methods: We conducted an observer-blinded, single-center, randomized controlled trial in infants admitted to the
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, University of Milan, Italy between 2009 and 2011. Inclusion
criteria were gestational age < 32 weeks and/or birth weight < 1500 g, and being fed human milk for < 20% of the total
milk intake. Exclusion criteria were congenital malformations or conditions that could interfere with growth or body
composition. Included infants were randomized to receive a standard full-term formula or a nutrient-enriched formula
up until 6 months of corrected age, using two computer-generated randomization lists; one appropriate for gestational
age (AGA) and one for small for gestational age (SGA) infants. We assessed neurodevelopment at 24 months of corrected
age using the Griffiths Mental Development Scale and related subscales (locomotor, personal-social, hearing and speech,
hand and eye coordination, and performance).
Results: Of the 207 randomized infants, 181 completed the study. 52 AGA and 35 SGA infants were fed a nutrient-
enriched formula, whereas 56 AGA and 38 SGA infants were fed a standard full-term formula. The general quotient at
24 months of corrected age was not significantly different between infants randomized to receive a nutrient-enriched
formula compared with a standard term formula up until 6 months of corrected age (AGA infants: 93.8 ± 12.6 vs. 92.4 ±
10.4, respectively; SGA infants: 96.1 ± 9.9 vs. 98.2 ± 9, respectively). The scores of related subscales were also similar
among groups.
Conclusions: This study found that feeding preterm infants a nutrient-enriched formula after discharge does not
affect neurodevelopment at 24 months of corrected age, in either AGA or SGA infants, free from major comorbidities.
Trial registration: Current Controlled Trials (http://www.controlled-trials.com/ISRCTN30189842) London, UK.
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Preterm infants are at increased risk of adverse neurodeve-
lopmental outcomes [1]. Adequate growth and nutrition
may play a key role in facilitating neurodevelopmental per-
formance [2]. Indeed, it is well acknowledged that early nu-
trition affects brain development both during fetal life and
in the first months after birth [3]. In the last decade, atten-
tion has focused on nutritional interventions that might
improve the growth and development of preterm infants.
Tan et al. [4] found that limiting early energy deficits by
providing high energy intake in association with increased
protein intake during the hospital stay, may support ad-
equate postnatal brain growth and improve neurodevelop-
mental indices at 3 months of corrected age.
Consistent with these findings, Stephens et al. [5] re-
ported a positive, independent association between first
week protein and energy intake, and Mental Develop-
mental Index Scores assessed using the Bayley Scales of
Infant Development II, in extremely preterm infants at
18 months of corrected age. To our knowledge, there is
paucity of data in the literature concerning the effect of
high protein and energy intake after hospital discharge
in preterm infants, who are randomized and separately
evaluated on neurodevelopmental outcome according to
intrauterine growth pattern.
Agosti et al. [6] conducted a multicenter, randomized
controlled trial on 121 very low-birth weight infants,
randomized at term-corrected age to receive either a
preterm formula or a standard term formula up until
55 weeks of corrected age. The authors analyzed
the small for gestational age (SGA) infants separately,
reporting a higher score on the Griffiths Developmen-
tal Scale at 6 months of corrected age in the infants fed
with preterm formula compared with the infants fed
the standard term formula.
Our group recently conducted a randomized trial
that investigated whether consumption of a nutrient-
enriched formula after hospital discharge leads to a dif-
ferent growth and weight gain composition in preterm
infants, randomized and evaluated according to intra-
uterine growth pattern.
We tested the hypothesis that preterm infants fed
nutrient-enriched formula between term age and 6 months
of corrected age would develop lower adiposity compared
with preterm infants fed standard formula. Beneficial effects
in terms of head circumference growth and fat free mass
gain were found in preterm infants born appropriate for
gestational age (AGA) who received a nutrient-enriched
formula after hospital discharge [7].
In this paper, we report the results concerning the sec-
ondary outcome of this randomized controlled study. We
evaluated whether the consumption of a nutrient-enriched
formula after hospital discharge could affect subsequent
neurodevelopment in preterm infants, evaluated separatelyaccording to intrauterine growth pattern. We tested the hy-
pothesis that preterm infants who had been fed a nutrient-
enriched formula for the first 6 months of corrected age
would show higher scores at 24 months of corrected age
on the Griffiths Mental Development Scale and related sub-
scales than infants that had been fed a standard formula.
Methods
Study design
The study was an observer-blinded, single-center, ran-
domized controlled trial. The results of this study are
reported following the CONSORT guidelines. Details of the
study are reported elsewhere [6]. The trial was registered
with Current Controlled Trials (http://www.controlled-trials.
com/ISRCTN30189842) London, United Kingdom.
At term-corrected age, the infants were randomized to
receive either a standard full-term formula (treatment
A) or a nutrient-enriched formula (treatment B) up until
6 months of corrected age. The introduction of any other
food before the infants were 6 months’ corrected age was
not allowed. After 6 months, the infants were weaned
according to our clinical practice complying with the rec-
ommendations of the European Society of Pediatric Gastro-
enterology and Nutrition [8].
Randomization for feeding with treatment A or B was
performed by an independent investigator using two
computer-generated randomization lists; one for AGA
infants and one for SGA infants, with a random per-
muted block size of four.
Compared with the standard full-term formula, the
nutrient-enriched formula provided higher energy (75 vs.
68 kcal/100 mL), protein (2.0 vs. 1.4 g/100 mL), protein-to-
energy ratio (2.6 vs. 2.0 g/100 kcal), carbohydrates (7.5 vs.
7.4 g/100 mL), fat (4.1 vs. 3.7 g/100 mL), docosahexaenoic
acid (14 vs. 8.5 mg/100 mL), arachidonic acid (18 vs.
14.9 mg/100 mL), vitamin D (1.7 vs. 1.2 μg/100 mL),
calcium (94 vs. 47 mg/100 mL), and phosphorus (50
vs. 33 mg/100 mL). At randomization, the parents were
instructed to record the daily quantities of milk consumed
by the infants in a diary. The average daily energy (kcal/kg/
day) and proteins (g/kg/day) were calculated up until
6 months of corrected age.
Subjects
The study was approved by the Ethics Committee of the
Fondazione Istituto di Ricovero e Cura a Carattere Scienti-
fico Cà Granda Ospedale Maggiore Policlinico and written
informed consent was obtained from the parents.
Among all consecutive newborns admitted to NICU,
Fondazione Istituto di Ricovero e Cura a Carattere
Scientifico Cà Granda Ospedale Maggiore Policlinico,
between 2009 and 2011, 211 preterm infants were en-
rolled in the study by a single investigator and 194 sub-
jects completed the study at 12 months of corrected age
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and/or birth weight < 1,500 g and being fed human milk
for < 20% of the total milk intake. Exclusion criteria
were congenital malformations or conditions that could
interfere with growth or body composition (including
congenital diseases, chromosomal abnormalities, chronic
lung disease, severe brain disease, severe metabolic dis-
ease, severe cardiac disease or gastrointestinal diseases).
Neonatal characteristics (gestational age, being AGA
or SGA, birth weight, length, and head circumference)
were recorded prospectively. Gestational age was based
on the mother’s last menstrual period and a first trimester
ultrasound examination. Corrected age was calculated
using the chronologic age and adjusting for gestational age,
i.e., the number of additional weeks from term (40 weeks).
Infants were categorized as AGA or SGA if the birth weight
was ≥ 10th or < 10th percentile, respectively, according to
Fenton’s growth chart [9]. We performed brain magnetic
resonance imaging (MRI) after a mean of 40 ± 2 weeks
postconceptional age in all newborns. To assess eligibility,
brain MRI results were screened for the presence of minor
brain lesions (e.g., mild gliosis, mild ventricular dilatation,
irregularly shaped ventricles or corpus callosum thinning)
[10], as the occurrence of major brain lesions was an exclu-
sion criteria. The maternal educational level (years) was also
obtained and categorized as follows: low (≤ 13); high (> 13).
Measurements
We assessed anthropometric parameters (weight, length,
and head circumference) and neurodevelopment at
24 months of corrected age. We measured anthropomet-
ric parameters according to standard procedures [11].
Neurodevelopment was assessed using the Griffiths
Mental Development Scale and related subscales (loco-
motor, personal-social, hearing and speech, hand and
eye coordination, and performance) by a single skilled
examiner, who was blinded to the infants’ randomization
[12]. A sub-quotient for each related subscale was calcu-
lated with a mean population value of 100 and a stand-
ard deviation of 16. A sub-quotient < 68 was classified
as severe developmental delay, whereas a sub-quotient
from 68 to 83 indicated mild mental retardation in the
domain investigated by the specific subscale.
A general quotient (GQ) was then calculated with a
mean population value of 100 and a standard deviation
of 12. A GQ < 76 was classified as severe developmen-
tal delay. A GQ from 76 to 87 indicated mild mental
retardation.
Adverse events
Adverse events (AEs) were assessed on the basis of in-
quires to the parents. All AEs were recorded on adverse
event forms and evaluated by the investigator for causal-
ity for the relationship to the study feeding and forseverity. An AE was defined as any event that was not
consistent with the information provided in the consent
form or could reasonably be expected to accompany the
natural history and progression of the subject’s condition
throughout the study. AEs were considered serious if they
were fatal or life-threatening, required hospitalization or
surgical intervention, resulted in persistent or signifi-
cant disability/incapacity, or were considered medically
relevant by the investigator. All other AEs were catego-
rized as nonserious. AEs were assessed according to
body system.Statistical analysis
Sample size was estimated using the value of the GQ.
To detect an 11-point (15 SD) difference in the GQ
[13] at 5% significance and 80% power, 30 infants in
each group were needed. Descriptive data are shown as
means ± SD or number of observations (percentages).
Comparisons between infants fed treatment A and in-
fants fed treatment B were performed within AGA and
SGA groups using the chi square test for discrete vari-
ables or analysis of variance for continuous variables.
All statistical analyses were conducted at the α = 0.05
level and were two-tailed. Statistical analysis was per-
formed with SPSS 12 (SPSS Inc., Chicago, IL).Results
Of the 194 infants who completed the study at 12 months
of corrected age, 181 underwent anthropometric and
neurodevelopment assessments (Figure 1). No differ-
ences between groups were found in baseline charac-
teristics except for mean protein intake between term
and 6 months of corrected age. The latter was higher
in infants fed the nutrient-enriched formula than in in-
fants fed the standard term formula, in both AGA and
SGA groups (Table 1). Anthropometric characteristics
at 24 months of corrected age are presented in Table 2.
In Table 3, the infants’ mean GQ and sub-quotients at
24 months are shown. No differences between groups
were found either in the GQ or in the sub-quotients.Adverse events
In total, 128 AEs occurred from enrollment up to the
end of the study. Of these, 14 occurring in 13 infants
were assessed as serious. Documented reasons for all
AEs were mostly illnesses that are common during the
first two years of life (ie, otitis media, bronchitis, gastro-
enteritis, upper respiratory tract infection, bronchiolitis,
pharyngitis, varicella, urinary tract infection). There were
no differences in the incidence of non serious and ser-
ious AEs among the groups.
Figure 1 Flow chart of the study.
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Significant effort has focused on the identification of
nutritional approaches applied early in life to improve
later neurodevelopment, especially for extremely pre-




Gestational age (weeks) 28.9 ± 1.9
Birth weight (g) 1146 ± 223
Birth length (cm) 36.5 ± 3
Birth HC° (cm) 26.4 ± 2
Twins n (%) 25 (48)
Males n (%) 26 (50)
Abnormal MRI n (%) 5 (10)
Protein intake (g/kg/day) 2.79 ± 0.42*
(Term-6 months corrected age)
Energy intake (kcal/kg/day) 109.6 ± 14.3
(Term-6 months corrected age)
Maternal education >13 years 24 (46)
°HC = head circumference.
*P < 0.001.
Data were analysed using the independent samples T test or the chi square test an
infants fed standard formula and between SGA infants fed enriched formula vs SGAContrary to our hypothesis, the present study was
unable to show that energy and protein supplementa-
tion led to better neurodevelopment of preterm infants
at 24 months of corrected age. The absence of a positive ef-
fect of nutritional supplementation on neurodevelopmentization
SGA
Treatment A Treatment B Treatment A
n = 56 n = 35 n = 38
29 ± 1.7 31.4 ± 1.9 31.6 ± 1.9
1197 ± 204 1103.4 ± 239 1129 ± 304
37.4 ± 2.8 36.5 ± 3.4 36.5 ± 3.8
27.1 ± 2.2 27 ± 2.4 27.2 ± 2.4
23 (41) 12 (34) 11 (29)
31 (60) 17 (49) 21 (55)
2 (4) 4 (11) 5 (13)
2.24 ± 0.49 2.94 ± 0.48* 2.26 ± 0.36
108.8 ± 17.6 110.2 ± 24.7 108.6 ± 12.7
23 (41) 18 (51) 18 (47)
d comparisons were made between AGA infants fed enriched formula vs AGA
infants fed standard formula.
Table 2 Growth parameters at 24 months of corrected age according to randomization
AGA SGA
Treatment B Treatment A Treatment B Treatment A
n = 52 n = 56 n = 35 n = 38
Weight (g) 11930 ± 1637 11662 ± 1219 10682 ± 1249 10793 ± 1445
Length (cm) 86.3 ± 4.3 85.6 ± 2.9 83.1 ± 2.7 83.4 ± 3.1
HC (cm) 48.1 ± 1.6 47.7 ± 1.7 47.7 ± 1.57 47.9 ± 1.17
Data were analysed using the independent samples T test and comparison was made between AGA infants fed enriched formula vs AGA infants fed standard
formula and between SGA infants fed enriched formula vs SGA infants fed standard formula.
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fants did not develop major comorbidities that could poten-
tially have interfered with neurodevelopment during their
hospital stay. However, in our study, the infants’ GQ and
sub-quotient scores were normal. This may suggest an
overall improvement in care in these vulnerable infants
who are at risk for adverse neurodevelopment because
brain development occurs primarily from being exposed to
non-physiological environmental influences [15].
The absence of any beneficial effect of the nutritional
intervention on neurodevelopment at 24 months of cor-
rected age could also be because the post-discharge
period may be less sensitive to the influence of energy
and protein supplementation than the pre-discharge
period [14].
Our findings are consistent with other studies [16-20]
that investigated the effect of protein and energy supple-
mentation after discharge on preterm infants’ neurode-
velopment. However, it must be underlined that in all
but one (ref. [20]) of these studies, the actual energy and
protein intake of the enrolled infants was not reported.
Therefore, it is not possible to make a comparison with
the actual protein and energy intake of infants enrolled
in the present study.
Young et al. [16] recently conducted a meta-analysis,
including two randomized controlled trials. They con-
cluded that the benefits of using energy and protein sup-
plementation after discharge in preterm infants are not
supported by the available evidence.Table 3 Infants’ general quotient and sub-quotients at 24 mo
AGA
Treatment B T
n = 52 n
General Quotient 93.8 ± 12.6 9
Locomotor 93.7 ± 12.6 9
Personal social 88.4 ± 15 8
Hearing and speech 93.3 ± 13.8 9
Hand and eye coordination 97.9 ± 14.6 9
Performance 96.5 ± 13 9
Data were analysed using the independent samples T test and comparison was ma
formula and between SGA infants fed enriched formula vs SGA infants fed standardIn one trial [17], randomized 113 preterm infants with
a birth weight < 1.75 g and < 34 weeks of gestation, were
fed either a preterm infant formula (2.2 g protein/100 ml
and 80 kcal/100 ml) or a term formula (1.4 g protein/
100 ml and 66 kcal/100 ml) from discharge until 6 months
of corrected age. Alternatively, they were fed the preterm
formula from discharge to full-term and the full-term
formula from full-term to 6 months of corrected age. The
authors reported no significant difference in mental or psy-
chomotor development at 18 months of age. In another
trial [18], 196 preterm infants weighing < 3.000 g at time of
discharge were randomly assigned to receive either a
nutrient-enriched post discharge formula (1.85 g protein/
100 ml and 72 kcal/100 ml) or a standard full-term formula
(1.45 g protein/100 ml and 68 kcal/100 ml) until 9 months’
post term. Developmental scores at 9 or 18 months,
assessed using the Bayley Scales of Infant Development II,
were similar between the groups. However, infants fed the
nutrient-enriched formula had a 2.8 point advantage in the
Psychomotor Development Index.
Jeon et al. [19] randomized preterm infants to one of
two conditions. Infants received either a preterm for-
mula (2.3 g protein/100 ml and 80 kcal/100 ml) or a
term formula (1.6 g protein/100 ml and 67 kcal/100 ml)
from term until 6 months of corrected age or a preterm
formula to 3 months of corrected age and then term for-
mula to 6 months of corrected age. They reported no
significant difference in neurodevelopment outcome at
18 months of corrected age, assessed using the Bayleynths according to randomization
SGA
reatment A Treatment B Treatment A
= 56 N = 35 N = 38
2.4 ± 10.4 96.1 ± 9.9 98.2 ± 9
5.07 ± 12.7 101.5 ± 6.8 96 ± 13.4
6.05 ± 13.7 91.11 ± 13.2 92.7 ± 10.1
0.9 ± 14 93.6 ± 13.3 96.1 ± 10.2
6.8 ± 10.2 99.7 ± 11.1 103.3 ± 8.09
6.4 ± 11.3 99.7 ± 7.4 101.3 ± 8.09
de between AGA infants fed enriched formula vs AGA infants fed standard
formula.
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gated the effect of breast milk fortification after dis-
charge, in a cohort of 39 preterm infants born at <
33 weeks gestation, with birth weights ranging from
750 g to 1800 g. The infants were randomized to receive
12 weeks of either 50% of the daily breast milk intake,
fortified to attain a protein and energy content of ap-
proximately 2.2 g and 81 kcal/100 ml, or unfortified
breast milk. Developmental outcome was assessed at
18 months corrected age, although many subjects were
lost to follow-up. The authors reported no significant
difference in developmental outcome between groups.
Nonetheless, it should be considered that the energy and
protein intake at 6 months of corrected age of the in-
fants in both groups of the study by Aimone et al. were
much lower than those consumed by the AGA and SGA
infants in the present study, irrespective of the type of
feeding.
Two trials conducted during a hospital stay have sup-
ported the hypothesis that nutritional supplementation
improves neurodevelopment [21-24]. However, these
studies addressed moderate preterm infants or displayed
methodological shortcomings (e.g., small sample size). A
beneficial effect of first-week protein and energy intake
on medium-term neurodevelopment has been reported
in an observational study [5]. However, randomized, con-
trolled trials are superior for cohort analysis because they
reduce the effects of known and unknown confounders.
The main strengths of the present study are that the
effect of a nutritional intervention on subsequent devel-
opment was analyzed in subgroups of AGA and SGA
preterm infants. Additionally, the actual energy and
protein intakes during the intervention period were col-
lected. Indeed, to our knowledge, studies investigating
the effect on neurodevelopmental outcome of high protein
and energy intake after hospital discharge in preterm in-
fants, who are randomized and evaluated separately accord-
ing to intrauterine growth pattern, are scarce. Agosti et al.
[6] reported interim results from a multi-center, random-
ized controlled study on 121 very low-birth weight infants.
Infants were randomized at term corrected age to receive
either a preterm formula (2.4 g/100 ml and 80 kcal/100 ml)
or a standard term formula (1.7 g/100 ml and 70 kcal/
100 ml) up until 55 weeks of corrected age. The authors fo-
cused on infants born SGA, reporting a beneficial effect of
the consumption of a preterm formula evidenced by a
higher score on the Griffiths Developmental Scale at
6 months of corrected age. However, the authors reported
neither the number of infants born SGA that were analyzed
nor their actual nutritional intakes.
The main limitation of our study could be that we did
not enroll infants affected by major comorbidities. These
infants may have benefited most from the nutritional
intervention.Conclusions
Based on our findings, feeding preterm infants a
nutrient-enriched formula after discharge does not ap-
pear to affect neurodevelopment at 24 months of cor-
rected age, in either AGA or SGA infants, free form
major comorbidities.
Further large, randomized controlled studies are indi-
cated to identify the potential positive effect of energy
and protein supplementation on preterm infants when
they are older, with a particular focus on the time of
school entry.
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